Core Insights - Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide to enhance patient care [4] - The company will be represented by Steve Lisi, Chairman & CEO, at the 38th Annual Roth Conference from March 22nd to 24th, 2026 [1][2] Company Overview - Beyond Air is dedicated to improving the lives of patients with respiratory illnesses, neurological disorders, and solid tumors through the use of nitric oxide [4] - The company has received FDA approval and CE Mark for its LungFit PH system, aimed at treating term and near-term neonates with hypoxic respiratory failure [4] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [4] Research and Development - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of nitric oxide with a proprietary delivery system for targeting specific solid tumors in pre-clinical studies [5]

Core Insights - Beyond Air has expanded its LungFit PH distribution network to 34 countries, covering a combined population of 2.7 billion people [1][3] - The company has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador [1][2] - The LungFit PH device generates nitric oxide from ambient air, eliminating the need for traditional high-pressure cylinders, thus streamlining hospital operations and reducing environmental impact [3][5] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide to improve patient outcomes [10][11] - The LungFit PH system is FDA-approved and designed for treating hypoxic respiratory failure in neonates, with potential applications for severe lung infections [11][12] - The company is advancing other LungFit systems in clinical trials for various respiratory and neurological conditions [11][12] Product Details - LungFit PH is a cylinder-free, phasic flow generator that can deliver nitric oxide at concentrations ranging from 1 ppm to 80 ppm [5][6] - The device is compatible with ventilators and aims to replace large, high-pressure nitric oxide cylinders, providing operational benefits in hospital settings [5][6] - Beyond Air intends to offer nitric oxide treatment in home settings, enhancing accessibility for patients [6][7] Market Position - The company is well-positioned to capture opportunities in both developed and emerging healthcare markets, with hospital tender submissions already underway [3][11] - Beyond Air's distribution agreements are expected to drive significant adoption of its products in the coming years [3][11]